At Ocelot Bio, our approach in the treatment of liver disease is focused on improving outcomes for patients with portal hypertension, such as hepatorenal syndrome with acute kidney injury (HRS-AKI), a serious and life-threatening consequence of end-stage liver disease (ESLD).
Aiming to achieve a delicate balance to improve ESLD patient outcomes
ESLD-induced portal hypertension can lead to substantial vasodilation resulting in plasma leakage throughout the abdomen and a significant drop in arterial pressure. This acute drop in arterial pressure triggers a large renal vasoconstriction response which, if left untreated, rapidly leads to renal failure. If renal failure occurs, patients often need both a liver and kidney transplant – and their probability of survival until transplant is significantly reduced.